Seminar given by Ajna Hamidovic, PharmD, MS
Department of Pharmacy Practice
University of Illinois at Chicago
Abstract: A significant barrier to drug development for smoking cessation is the inability to deliver therapeutic compounds through the blood brain barrier. The direct nose-to- brain delivery, which is accomplished by a targeted deposition of compounds to the highly innervated olfactory region, my overcome this difficulty. We administered intranasal insulin to abstinent smokers in two clinical trials and showed that the neuropeptide rapidly decreases nicotine cravings. I will first describe neurobiological basis for CNS insulin therapy, followed by regulatory challenges in obtaining IND approval. I will also review the nose-to- brain pathway as well as present results of our clinical trial. The novel nicotine dependence pharmacotherapy with intranasal insulin has an overarching goal of reducing morbidity and mortality caused by smoking.
Room B36 COP/ Room E226 Rockford PHARM College of Pharmacy
General public/Campus community/Faculty/Staff/Students/Alumni/Prospective students
Lectures, Seminars and Meetings
Department of Biopharmaceutical Sciences